FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v AstraZeneca AB (No 5) [2013] FCA 560
Citation: Apotex Pty Ltd v AstraZeneca AB (No 5) [2013] FCA 560 Parties: APOTEX PTY LTD v ASTRAZENECA AB and ASTRAZENECA PTY LIMITED
WATSON PHARMA PTY LTD v ASTRAZENECA AB and ASTRAZENECA PTY LIMITED
ASTRAZENECA AB and ASTRAZENECA PTY LIMITED v ASCENT PHARMA PTY LTD ACN 118 734 795
File number(s): NSD 673 of 2011
NSD 2342 of 2011
NSD 208 of 2012Judge: JAGOT J Date of judgment: 11 June 2013 Catchwords: PATENTS – costs – further orders of invalidity Legislation: Federal Court Rules 2011 (Cth) Cases cited: Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162
Bradken Resources v Lynx Engineering Consultants (No. 2) [2012] FCA 1478
Doric Products v Lockwood Security (2002) 54 IPR 495; [2002] FCA 282
In NSD 673 of 2011: Counsel for the Applicant: Mr A J Maryniak Solicitor for the Applicant: Herbert Smith Freehills Counsel for the Respondents: Mr D Kell Solicitor for the Respondents: Ashurst Australia In NSD 2342 of 2011: Counsel for the Applicant: Mr A J Ryan SC and Mr I P Horak Solicitor for the Applicant: King & Wood Mallesons Counsel for the Respondents: Mr D Kell Solicitor for the Respondents: Ashurst Australia In NSD 208 of 2012: Counsel for the Applicants: Mr D Kell Solicitor for the Applicants: Ashurst Australia Counsel for the Respondent: Mr A J Ryan SC and Mr I P Horak Solicitor for the Respondent: King & Wood Mallesons
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 673 of 2011
BETWEEN: APOTEX PTY LTD
Applicant/Cross RespondentAND: ASTRAZENECA AB
First Respondent/Cross ClaimantsASTRAZENECA PTY LIMITED
Second Respondent/Cross-Claimants
JUDGE:
JAGOT J
DATE OF ORDER:
5 MARCH 2013
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Apotex Pty Limited (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed, excluding the costs of Apotex Pty Limited incurred in connection with its application for indemnity costs.
2.To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 2342 of 2011
BETWEEN: WATSON PHARMA PTY LTD
Applicant/Cross Respondent
AND: ASTRAZENECA AB
First Respondent/Cross ClaimantASTRAZENECA PTY LIMITED
Second Respondent/Cross Claimant
JUDGE:
JAGOT J
DATE OF ORDER:
5 MARCH 2013
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.Subject to order 2 below:
a.Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;
b.Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.
2.Order 1 be stayed:
a.Initially for a period of…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v AstraZeneca AB (No 5) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 560
- Decision Date
CaseChat Overview and Summary
The court first considered the applicable rules governing the proceedings. The case was initiated in May 2011 under the previous Federal Court Rules, but later expanded to include additional patents, with all significant procedural steps occurring after the implementation of the new Federal Court Rules in August 2011. The court held that the new rules should apply to the proceedings, including the offers of compromise made by Apotex. The court concluded that there was no basis to apply the old rules, as all offers of compromise were made under the new rules. The court further ruled that the new rules were not less generous to a party making an offer to settle the proceedings and that Apotex's offers were explicitly made in accordance with the new rules.
The court ordered that AstraZeneca AB and AstraZeneca Pty Ltd were to pay the costs of Apotex, Watson Pharma, and Ascent, excluding the costs incurred by Apotex in connection with its application for indemnity costs. The court also granted leave for the AstraZeneca parties to appeal the orders for costs and the revocation of certain patent claims. The revocation of specific claims of the patents held by AstraZeneca was stayed for 21 days, or until the final determination of any appeal, if lodged within that period. The orders provided for the revocation of claims 6 and 19 to 25 of Australian Patent No 2000051842 and claims 11 to 20, 22, and 23 of Australian Patent No 2002214165, contingent on the outcome of any appeals.
Orders
Orders of the court
1. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Apotex Pty Limited (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed, excluding the costs of Apotex Pty Limited incurred in connection with its application for indemnity costs.
2. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
1. Subject to order 2 below:
a. Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;
b. Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.
2. Order 1 be stayed:
a. Initially for a period of 21 days from the date on which these orders are pronounced; and
b. If an appeal is lodged within that period, until the final determination of that appeal, or further order.
3. To the extent necessary, leave is granted to the AstraZeneca parties to appeal order 1 above.
4. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Watson Pharma Pty Ltd (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed.
5. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
6. Subject to order 2 below:
a. Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;
b. Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.
7. Order 1 be stayed:
a. Initially for a period of 21 days from the date on which these orders are pronounced; and
b. If an appeal is lodged within that period, until the final determination of that appeal, or further order.
8. To the extent necessary, leave is granted to the AstraZeneca parties to appeal order 1 above.
9. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Ascent Pharma Pty Ltd (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed.
10. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.